Wagner C R, Bergstrom C P, Koning K R, Hanna P E
Department of Medicinal Chemistry, University of Minnesota, Minneapolis 55455, USA.
Drug Metab Dispos. 1996 Feb;24(2):245-53.
Two isozymes of arylamine N-acetyltransferases (NATs) catalyze the biotransformation of arylamines to arylamides, and the bioactivation of carcinogenic arylhydroxylamines and arylhydroxamic acids to reactive electrophiles capable of forming a variety of DNA and protein adducts. As part of a project directed toward delineation of the molecular factors responsible for the pronounced differences in the substrate specificity of the isozymes, we have recently reported the expression in Escherichia coli and purification of hamster NAT1 (NAT1 8) as a fusion protein to an antibody-reactive amino terminus FLAG peptide capable of being removed by digestion with enterokinase. Unfortunately, the conditions necessary for the removal of the peptide by enterokinase resulted in incomplete protease digestion and substantial loss of NAT1 activity. Consequently, we have constructed the plasmid pPH8 in which an 11 amino acid thrombin proteolysis site has been inserted between the FLAG peptide and the amino terminus of NAT1. In addition, a plasmid that expresses hamster NAT2 (NAT2 15) was constructed by exchanging the gene sequence for NAT1 with the cloned sequence for NAT2. Both NAT fusion proteins were expressed in JM105 cells. Analysis of catalytically active cell lysates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that approximately 30-fold more soluble NAT2 was expressed than NAT1 in the bacterial cytosol. The fusion proteins were purified to homogeneity by immunoaffinity chromatography, followed by gel filtration to remove high molecular weight contaminants. The FLAG peptide was subsequently removed by treatment with human thrombin, followed by an additional pass over the immunoaffinity column. Unlike the results obtained from proteolysis by enterokinase, the activities of the rNAT1 and rNAT2 were shown to be unaffected by treatment with thrombin. Moreover, the substrate specificities for the recombinant NATs closely matched those observed for NAT1 and NAT2 isolated from hamster liver.
芳胺N - 乙酰基转移酶(NATs)的两种同工酶催化芳胺向芳酰胺的生物转化,以及致癌性芳基羟胺和芳基异羟肟酸向能够形成多种DNA和蛋白质加合物的活性亲电试剂的生物活化。作为旨在阐明负责同工酶底物特异性显著差异的分子因素的项目的一部分,我们最近报道了仓鼠NAT1(NAT1 8)在大肠杆菌中的表达及其作为融合蛋白纯化至抗体反应性氨基末端FLAG肽,该肽可通过肠激酶消化去除。不幸的是,肠激酶去除该肽所需的条件导致蛋白酶消化不完全以及NAT1活性大量丧失。因此,我们构建了质粒pPH8,其中在FLAG肽和NAT1的氨基末端之间插入了一个11个氨基酸的凝血酶蛋白水解位点。此外,通过用NAT2的克隆序列替换NAT1的基因序列构建了表达仓鼠NAT2(NAT2 15)的质粒。两种NAT融合蛋白均在JM105细胞中表达。通过十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳对具有催化活性的细胞裂解物进行分析表明,在细菌胞质溶胶中表达的可溶性NAT2比NAT1多约30倍。融合蛋白通过免疫亲和色谱纯化至同质,随后进行凝胶过滤以去除高分子量污染物。随后通过用人凝血酶处理去除FLAG肽,然后再通过免疫亲和柱。与肠激酶蛋白水解获得的结果不同,rNAT1和rNAT2的活性显示不受凝血酶处理的影响。此外,重组NATs的底物特异性与从仓鼠肝脏分离的NAT1和NAT2所观察到的底物特异性密切匹配。